# Applied Therapeutics Reports Third Quarter 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-third-quarter-2025-financial-results
Ticker: APLT
Company: Applied Therapeutics
Source: Applied Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.appliedtherapeutics.com
## Summary

– Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes – Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia – New data on govorestat for the treatment of PMM2-CDG

## Article Body
– Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes – Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia – New data on govorestat for the treatment of PMM2-CDG published
## Recent Company News
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports First Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-first-quarter-2025-financial-results) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-presents-full-12-month-clinical-results-and-new-topline-data-from-inspire-phase-2-3-trial-of-govorestat-in-cmt-sord-in-late-breaking-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Key Leadership Appointments](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-key-leadership-appointments) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports Second Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-second-quarter-2025-financial-results) — Source: Applied Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)